Blog
Insights on account research, sales intelligence, and B2B selling from the Salesmotion team.
AI Readiness Signals: Which Accounts Will Buy AI Services
AI readiness signals tell you which accounts will buy AI services. A five-stage maturity model from public evidence, a signal table, and a worked example.
Find Bioequivalence Study Sponsors Before They Pick a CRO
Where bioequivalence study sponsors show up before a registry does: Orange Book expiry dates, Paragraph IV data, FDA guidances, and a molecule-first list.
Compelling Events in Sales: How to Find the 'Why Now'
A compelling event in sales is a dated business event with a cost of inaction. 14 examples, where each shows up publicly, and how to rank a territory.
Cross-Account Search: Find Which Accounts Are Moving
Cross-account search lets reps query their whole account list in one pass to find which accounts are moving on a topic, signal, or initiative.
How to Sell to Banks: Signals, Stakeholders and Timing
How to sell to banks: how vendor risk and the buying committee work, the public data that shows which banks to target, a signal table and an example.
Account Discovery vs Monitoring: Which Do You Need?
Account discovery vs monitoring: a no-spin guide to which sales motion fits your team, when each wins, and how to qualify before you buy.
PDUFA Dates, NDA and BLA Filings as Sales Triggers
Use a PDUFA date as a sales trigger: the Phase 3 to launch milestone chain, FDA review clocks, which vendors buy when, and where each event appears first.
Sales Tools for Individual Reps: Buy Your Own?
When a rep should buy their own sales tools: the break-even math, what to check with your employer first, and how to turn it into a team case.
What a Bioanalytical CRO Should Track, and What to Ignore
Most signal lists are written for full-service CROs. For a bioanalytical lab the useful set is much narrower: PK and bioequivalence starts, first-in-human, biosimilars, and the filings that fund them.
Should Your CRO Build a Claude Agent for Sponsor Research, or Buy One?
A build vs buy AI agent decision for life sciences BD teams: what a weekend agent on ClinicalTrials.gov genuinely does, what it cannot do, and the maintenance bill nobody quotes.
From Export to Chart: How CRO Leaders Build a Pipeline View by Indication and Phase
Business unit heads ask the same four questions about a therapeutic area. Here is the dataset that answers them, how to assemble it from trial registry data, and the four charts worth maintaining.
Territory Planning for CRO BD Teams, State by State
Country-level territories put half the US pipeline in one rep's patch. Here is how to build a state-level sponsor universe from registry data, balance it by trial volume rather than headcount, and keep it current.
How to Find Clinical Trial Sponsors Before They Pick a CRO
By the time an RFP lands, the decision is largely made. Here are the five registry events and three non-registry precursors that tell you a sponsor is approaching a CRO decision, and a weekly routine for working them.
GlobalData Alternatives for Mid-Size CROs
GlobalData is built for research and forecasting. A five to twenty person BD team has a different job. Here is an honest comparison by job to be done, what is publicly known about pricing, and how to switch without losing history.
Industry vs Academic Sponsors: Filtering University Hospitals Out of Your List
Most trial registry searches return a majority of academic sponsors. Here is how sponsor class actually works in the registry, why UK and EU results skew academic, and how to filter them out today.
One Seat, One Month: Running a Sales Intelligence Trial Inside a Large CRO
A single rep can prove or disprove a sales intelligence tool in thirty days without involving procurement. Here is the account selection, the weekly log, the four numbers a manager cares about, and a one-page report template.
Sterilization Decision Signals in Drug Development
Sterilization and packaging suppliers sell into a decision that happens once per programme. Here is where it sits on the development timeline, and the public signals that tell you a programme is approaching it.
Account Discovery vs. Account Intelligence: Two Different Products
Finding companies you have never heard of and knowing what to do with the ones you already target are different problems solved by different tools. Here is how to tell which one you need.
Bad Leads Kill Tool Adoption
Sales tools rarely fail on features. They fail when the first few outputs a rep checks turn out to be wrong, and the rep stops checking. How data quality determines adoption.
Finding Preclinical and Stealth Biotechs: What's Actually Discoverable
Preclinical companies leave a thin public trail. Here is exactly which signals exist before a trial registration, which do not, and how to build a discovery process around the real limits.
What Life Sciences BD Teams Get Wrong About Contact Seniority
Most contact databases skew toward the C-suite while the people who actually scope and select vendors sit two levels down. Why that happens, and how to target the real buying committee.
Selling Into Non-English Markets: Where Signal Coverage Breaks
Buying-signal tools are built on public web content, and that content is not evenly distributed. An honest map of where signal coverage is strong, where it thins out, and how to evaluate it for your territory.
Signal Relevance Beats Signal Volume
Pulling lots of data is table stakes. Deciding what matters is the hard part. How to evaluate a signal platform on relevance rather than coverage, and why volume metrics mislead.
Why Your AI SDR Pilot Failed
A post-mortem framework for AI SDR pilots that did not work. The four failure modes, how to tell which one you hit, and what to do differently before trying again.